Novartis (AG) v Ivax Pharmaceuticals UK Ltd

Novartis (AG) v Ivax Pharmaceuticals UK Ltd

Equoral does not infringe the patent because the majority of the active ingredient is not carried by microemulsion-sized particles, which is the core teaching and purpose of the patent. Additionally, Equoral does not contain a lipophilic phase as required by the claim, as its candidate component is amphiphilic and does not meet the patent's requirements.

Parties
Claimant/appellant: Novartis AG; Defendant/respondent: IVAX Pharmaceuticals UK Limited
Jurisdiction
England and Wales
Judgment Date
18 October 2007
Procedural Posture
Civil Appeal (patent Infringement) / Appeal From High Court (patents Court)
Outcome
Appeal dismissed
Legal Topics
Patent Infringement, Claim Construction, Pharmaceutical Patents

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 2 Party arguments 2 Amounts and remedies 2
Sign in to unlock

Parties

Novartis AG

Claimant/appellant

IVAX Pharmaceuticals UK Limited

Defendant/respondent

Procedural Posture

Civil Appeal (patent Infringement) / Appeal From High Court (patents Court)

  1. 1 Whether IVAX's Equoral product infringes Novartis's UK patent No. 2,222,770
  2. 2 Proper construction of 'oil-in-water microemulsion pre-concentrate' in the patent claim
  3. 3 Whether Equoral contains a 'lipophilic phase' as required by the claim

Ratio Decidendi

Equoral does not infringe the patent because the majority of the active ingredient is not carried by microemulsion-sized particles, which is the core teaching and purpose of the patent. Additionally, Equoral does not contain a lipophilic phase as required by the claim, as its candidate component is amphiphilic and does not meet the patent's requirements.

Court Disposition

Appeal dismissed

Orders

  • Appeal dismissed; High Court decision of non-infringement affirmed